Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Phase IIa study of Santarus' SAN-300 in rheumatoid arthritis begins

Dec. 30, 2013

CHMP gives positive opinion on subcutaneous tocilizumab

Dec. 27, 2013

Auxilium Pharmaceuticals submits supplemental BLA to the FDA for Xiaflex

Dec. 24, 2013

Biogen Idec opts in to commercialization agreement for anti-TNF biosimilars in Europe

Dec. 23, 2013

Potent ROR-gamma inverse agonist demonstrates efficacy in a murine model of arthritis

Dec. 20, 2013

Novel antibodies for autoimmune disorders disclosed by German scientists

Dec. 19, 2013

Novel BTK inhibitors patented by Pharmascience

Dec. 18, 2013

Asahi Kasei Pharma presents promising phase I results for AK-106-001616

Dec. 17, 2013

Covagen secures series B financing to advance COVA-322

Dec. 12, 2013

Glenmark Pharmaceuticals discloses novel ROR-gamma modulators

Dec. 5, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...